Personalizing oncology: Perspectives and prospects

Journal of Clinical Oncology

Volumn 31, Issue 15, 2013, Pages 1904-1911

  Mendelsohn, John ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLIC ACID; INDIUM 111; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; RNA; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKER;

CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL HETEROGENEITY; CELL PLASTICITY; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG METABOLISM; DRUG TARGETING; GENE SEQUENCE; GENETIC ANALYSIS; GENOME ANALYSIS; HEALTH CARE COST; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; ONCOLOGY; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; DRUG ANTAGONISM; FORECASTING; GENETIC PREDISPOSITION; GENETICS; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; PERSONALIZED MEDICINE;

ANTINEOPLASTIC AGENTS; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84880473776     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.3605     Document Type: Review

References (56)

1. Bishop JM: Cellular oncogenes and retroviruses. Annu Rev Biochem 52:301-354, 1983
2. Weinberg RA: Tumor suppressor genes. Science 254:1138-1146, 1991
3. de Kruif P: Microbe Hunters. San Diego, CA, Harcourt, Brace, and Co, 1926, pp 326
4. Gilman A, Philips FS: The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science 103:409-436, 1946
5. Farber S, Diamond LK: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid. N Engl J Med 238:787-793, 1948
6. Miller RA, Maloney DG, Warnke R, et al: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517-522, 1982
7. Kawamoto T, Sato JD, Le A, et al: Growth stimulation of A431 cells by EGF: Identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 80:1337-1341, 1983
8. Gill GN, Kawamoto T, Cochet C, et al: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259:7755-7760, 1984
9. Masui H, Kawamoto T, Sato JD, et al: Growth inhibition of human tumor cells in athymic mice by anti-EGF receptor monoclonal antibodies. Cancer Res 44:1002-1007, 1984
10. Divgi CR, Welt C, Kris M, et al: Phase I and imaging trial of indium-111 labeled anti-EGF receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83:97-104, 1991
11. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000
12. Mendelsohn J: Blockade of receptors for growth factors: An anticancer therapy - The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clin Cancer Res 6:747-753, 2000
13. Drebin JA, Link VC, Weinberg RA, et al: Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci U S A 83:9129-9133, 1986
14. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
15. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
16. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
17. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
18. Lander ES, Linton LM, Birren B, et al: Initial sequencing and analysis of the human genome. Nature 409:860-921, 2001
19. Venter JC, Adams MD, Myers EW, et al: The sequence of the human genome. Science 291:1304-1351, 2001
20. Chapman MA, Lawrence MS, Keats JJ, et al: Initial genome sequencing and analysis of multiple myeloma. Nature 471:467-472, 2011
21. Berger MF, Lawrence MS, Demichelis F, et al: The genomic complexity of primary human prostate cancer. Nature 470:214-220, 2011
22. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011
23. Masica DL, Karchin R: Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res 71:4550-4561, 2011
24. Boehm JS, Hahn WC: Towards systematic functional characterization of cancer genomes. Nat Rev Genet 12:487-498, 2011
25. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
26. Jones S, Zhang X, Parsons DW, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806, 2008
27. Rodríguez-Paredes M, Esteller M: Cancer epigenetics reaches mainstream oncology. Nat Med 17:330-339, 2011
28. Iorio MV, Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics - A comprehensive review. EMBO Mol Med 4:143-159, 2012
29. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
30. Marshall CJ: Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185, 1995
31. Dorsey FC, Steeves MA, Cleveland JL: Apoptosis, autophagy, and necrosis, in Mendelsohn JM, Howley PM, Israel MA, et al (eds): The Molecular Basis of Cancer. Philadelphia, PA, Elsevier, 2008, pp 205-220
32. Edinger AL, Thompson CB: Defective autophagy leads to cancer. Cancer Cell 4:422-424, 2003
33. Campisi J: Suppressing cancer: The importance of being senescent. Science 309:886-887, 2005
34. Chao DT, Korsmeyer SJ: BCL-2 family: Regulators of cell death. Annu Rev Immunol 16:395-419, 1998
35. Dameshek W, Gunz F: Leukemia (ed 2). New York, NY, Grune and Stratton, 1964, pp 175-182
36. Metcalf D, Moore MAS: Haemopoietic Cells. New York, NY, Elsevier, 1971
37. Brabletz T: To differentiate or not: Routes towards metastasis. Nat Rev Cancer 12:425-436, 2012
38. Gupta PB, Onder TT, Jiang G, et al: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138:645-659, 2009
39. Shah NP, Skaggs BJ, Branford S, et al: Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117:2562-2569, 2007
40. Amit I, Citri A, Shay T, et al: A module of negative feedback regulators defines growth factor signaling. Nat Genet 39:503-512, 2007
41. Frei E 3rd, Freireich EJ: Progress and perspectives in the chemotherapy of acute leukemia. Adv Chemother 2:269-298, 1965
42. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
43. De Palma M, Hanahan D: The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities. Mol Oncol 6:111-127, 2012
44. Kim ES, Herbst RS, Wistuba II, et al: The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov 1:44-53, 2011
45. Tsimberidou AM, Iskander NG, Hong DS, et al: Personalized medicine in a phase 1 clinical trials program: The MD Anderson Cancer Center initiative. J Clin Oncol 29:165s, 2011 (suppl; abstr CRA2500)
46. Janku F, Tsimberidou AM, Garrido-Laguna I, et al: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10:558-565, 2011
47. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
48. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
49. Roychowdhury S, Iyer MK, Robinson DR, et al: Personalized oncology through integrative high-throughput sequencing: A pilot study. Sci Transl Med 3:111ra121, 2011
50. Dalton WS, Sullivan DM, Yeatman TJ, et al: The 2010 Health Care Reform Act: A potential opportunity to advance cancer research by taking cancer personally. Clin Cancer Res 16:5987-5996, 2010
51. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
52. Scartozzi M, Gaimpieri R, Maccaroni E, et al: Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. J Transl Med [epub ahead of print April 10, 2012]
53. Misale S, Yaeger R, Hobor S, et al: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532-536, 2012
54. Diaz LA Jr, Williams RT, Wu J, et al: The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537-540, 2012
55. Institute of Medicine: Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC, National Academies Press, 2012
56. Hudson KL: Genomics, health care, and society. N Engl J Med 365:1033-1041, 2011